Patents by Inventor Lian WU

Lian WU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9365589
    Abstract: In its many embodiments, the present invention provides certain C2-ring-substituted iminothiazine compounds, including compounds Formula (I): (structurally represented) or a tautomers thereof, and pharmaceutically acceptable salts of said compounds and, wherein R1, R2, R3, R4, X, ring A, RA, m, -L1-, and RL are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: June 14, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jared N. Cumming, David Earl Kaelin, Jr., Jack D. Scott, Wen-Lian Wu, Duane A. Burnett
  • Patent number: 9364510
    Abstract: A botanical composition and combinations thereof that include a leaf extract of Hylotelephium spectabile (Boreau) H. Ohba and is useful for treating and/or preventing histamine-mediated conditions or disorders are described. Methods of manufacture and use thereof are also described.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: June 14, 2016
    Assignee: MARVPHYT DEVELOPMENT LLC
    Inventors: Xi Juan Liang, Bing Lian Wu
  • Publication number: 20160016975
    Abstract: In its many embodiments, the present invention provides certain C2-azaspiro substituted iminothiazine dioxide compounds. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.
    Type: Application
    Filed: March 11, 2014
    Publication date: January 21, 2016
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Eric J. Gilbert, Jared N. Cumming, Jack D. Scott, Wen-Lian Wu, Duane A. Burnett, Andrew W. Stamford
  • Patent number: 9226927
    Abstract: Disclosed herein are compounds of Formula (I) (I) and pharmaceutically acceptable salts thereof, wherein each of the substituents is given the definition as set forth in the specification and claims. Also disclosed are pharmaceutical compositions containing the compound of Formula (I) and use of the compound in the treatment of neurodegenerative diseases or conditions such as Alzheimer's disease.
    Type: Grant
    Filed: September 4, 2012
    Date of Patent: January 5, 2016
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Wen-Lian Wu, Duane A. Burnett
  • Publication number: 20150372588
    Abstract: A control circuit in a power factor correction (PFC) circuit includes: a multiplier, used for multiplying a voltage sampling signal by a feedback signal, and outputting a first signal; and a waveform generating module, used for generating a second signal related to a filter capacitor connected in parallel to an input end and/or an output end of a rectifier bridge. A control signal for controlling a state of a main switch transistor is generated by using the first signal, the second signal, and a current sampling signal of the main switch transistor in the PFC circuit.
    Type: Application
    Filed: December 4, 2013
    Publication date: December 24, 2015
    Applicant: INVENTRONICS (HANGZHOU), INC.
    Inventors: Delai JIANG, Liang'an GE, Lian WU
  • Publication number: 20150344500
    Abstract: In its many embodiments, the present invention provides certain C2-ring-substituted iminothiazine compounds, including compounds Formula (I): (structurally represented) or a tautomers thereof, and pharmaceutically acceptable salts of said compounds and, wherein R1, R2, R3, R4, X, ring A, RA, m, -L1-, and RL are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.
    Type: Application
    Filed: December 16, 2013
    Publication date: December 3, 2015
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Jared N. Cumming, David Earl Kaelin, Jr., Jack D. Scott, Wen-Lian Wu, Duane A. Burnett
  • Patent number: 9186817
    Abstract: A method for preparing tobramycin sulfate powder for injection is provided. The method includes steps of providing a sterile tobramycin sulfate solution; and aseptically spray drying the tobramycin sulfate solution to obtain the tobramycin sulfate powder.
    Type: Grant
    Filed: August 1, 2013
    Date of Patent: November 17, 2015
    Assignee: Sunny Pharmtech Inc.
    Inventors: Yen-Chih Lin, Yon-Lian Wu
  • Patent number: 9181236
    Abstract: In its many embodiments, the present invention provides certain iminothiazine dioxide compounds, including compounds Formula (I): and tautomers and stereoisomers thereof, and pharmaceutically acceptable salts of said compounds, said tautomeros and said stereoisomers, wherein each of the variables shown in the formula are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including Alzheimer's disease, are also disclosed.
    Type: Grant
    Filed: August 21, 2012
    Date of Patent: November 10, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Wen-Lian Wu, Duane A. Burnett, Andrew W. Stamford, Jared N. Cumming, Theodros Asberom, Chad Bennett, Thavalakulamgara K. Sasiskumar, Jack D. Scott
  • Patent number: 9072669
    Abstract: The preparation of Pleurotus tuber-regium polysaccharide functionalized nano-selenium hydrosol with anti-tumor activity includes the following steps: 1) at normal temperature and under normal pressure, adding a Vitamin C solution to an aqueous solution of Pleurotus tuber-regium polysaccharides, and mixing uniformly; 2) adding dropwise a selenium dioxide solution or a selenite solution to the solution while mixing uniformly; and 3) adding water to the solution to a pre-determined volume, to obtain a Pleurotus tuber-regium polysaccharide functionalized nano-selenium hydrosol when the red color of the product is no longer deepened. The polysaccharides are used to control the particle size of nano-selenium, to obtain functionalized nano-elemental selenium with high anti-tumor activity and low toxicity. The anti-tumor activity of the biologically active molecule polysaccharides and the physiological effect of nano-selenium are combined, and a synergistic anti-tumor effect is achieved.
    Type: Grant
    Filed: July 25, 2012
    Date of Patent: July 7, 2015
    Assignee: THE HONG KONG POLYTECHNIC UNIVERSITY
    Inventors: Tianfeng Chen, Ka Hing Wong, Hua-Lian Wu, Wenjie Zheng, Man Kin Wong, Wing Yin Cornelia Man
  • Patent number: 9051329
    Abstract: The present invention is directed to novel tricyclic heterocycles of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
    Type: Grant
    Filed: July 2, 2012
    Date of Patent: June 9, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventor: Wen-Lian Wu
  • Publication number: 20150061169
    Abstract: A method for preparing acetazolamide sodium powder for injection is provided. The method includes steps of providing an acetazolamide sodium solution; and aseptically spray drying the acetazolamide sodium solution to obtain the acetazolamide sodium powder.
    Type: Application
    Filed: August 30, 2013
    Publication date: March 5, 2015
    Applicant: SCI Pharmtech, Inc.
    Inventors: Yen-Chih Lin, Yon-Lian Wu
  • Publication number: 20150035182
    Abstract: A method for preparing tobramycin sulfate powder for injection is provided. The method includes steps of providing a sterile tobramycin sulfate solution; and aseptically spray drying the tobramycin sulfate solution to obtain the tobramycin sulfate powder.
    Type: Application
    Filed: August 1, 2013
    Publication date: February 5, 2015
    Applicant: SCI Pharmtech, Inc.
    Inventors: Yen-Chih Lin, Yon-Lian Wu
  • Patent number: 8933116
    Abstract: Disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein each of the substituents is given the definition as set forth in the specification and claims. Also disclosed are pharmaceutical compositions containing the compound of Formula (I) and use of the compound in the treatment of neurodegenerative diseases or conditions such as Alzheimer's disease.
    Type: Grant
    Filed: April 4, 2012
    Date of Patent: January 13, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Wen-Lian Wu, Duane A. Burnett, William J. Greenlee
  • Publication number: 20140227302
    Abstract: Disclosed herein are compounds of Formula (I) (I) and pharmaceutically acceptable salts thereof, wherein each of the substituents is given the definition as set forth in the specification and claims. Also disclosed are pharmaceutical compositions containing the compound of Formula (I) and use of the compound in the treatment of neurodegenerative diseases or conditions such as Alzheimer's disease.
    Type: Application
    Filed: September 4, 2012
    Publication date: August 14, 2014
    Inventors: Wen-Lian Wu, Duane A. Burnett
  • Publication number: 20140199421
    Abstract: A botanical composition and combinations thereof that include a leaf extract of Hylotelephium spectabile (Boreau) H. Ohba and is useful for treating and/or preventing histamine-mediated conditions or disorders are described. Methods of manufacture and use thereof are also described.
    Type: Application
    Filed: January 21, 2014
    Publication date: July 17, 2014
    Applicant: MarvPhyt Development LLC
    Inventors: Xi Juan Liang, Bing Lian Wu
  • Publication number: 20140200213
    Abstract: In its many embodiments, the present invention provides certain iminothiazine dioxide compounds, including compounds Formula (I): and tautomers and stereoisomers thereof, and pharmaceutically acceptable salts of said compounds, said tautomeros and said stereoisomers, wherein each of the variables shown in the formula are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including Alzheimer's disease, are also disclosed.
    Type: Application
    Filed: August 21, 2012
    Publication date: July 17, 2014
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Wen-Lian Wu, Duane A. Burnett, Andrew W. Stamford, Jared N. Cumming, Theodros Asberom, Chad Bennett, Thavalakulamgara K. Sasiskumar, Jack D. Scott
  • Patent number: 8729300
    Abstract: The present invention provides a simple, safe and more efficient process for preparing metal salts of valproic acid. The process includes steps of: (i) mixing valproic acid and a metal hydroxide (either dry solid or aqueous solution) in a drier to form a reaction mixture; and (ii) removing water, which is produced during the step of mixing the valproic acid and the metal hydroxide, from the reaction mixture to obtain the desired metal salts of valproic acid.
    Type: Grant
    Filed: August 11, 2009
    Date of Patent: May 20, 2014
    Assignee: Sci Pharmtech, Inc.
    Inventors: Wen-Chih Chuo, Weichyun Wong, Yon-Lian Wu
  • Publication number: 20140128382
    Abstract: The present invention discloses certain iminothiazine compounds and mono- and dioxides thereof, including compounds Formula (I): and tautomers and stereoisomers thereof, and pharmaceutically acceptable salts of said compounds, said tautomers and said stereoisomers, wherein each of variables shown in the formula are as defined herein. The compounds of the invention may be useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and uses, including Alzheimer's disease, are also disclosed.
    Type: Application
    Filed: April 12, 2012
    Publication date: May 8, 2014
    Inventors: Wen-Lian Wu, Duane A. Burnett, Andrew W. Stamford, Jared N. Cumming, Chad E. Bennett, Eric J. Gilbert, Jack D. Scott, Younong Yu, Xuanjia Peng
  • Publication number: 20140113920
    Abstract: The present invention is directed to novel tricyclic heterocycles of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
    Type: Application
    Filed: July 2, 2012
    Publication date: April 24, 2014
    Applicant: MERCK SHARP & DOHME CORP.
    Inventor: Wen-Lian Wu
  • Patent number: 8691832
    Abstract: The present invention is directed to novel tricyclic heterocycles of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
    Type: Grant
    Filed: December 1, 2011
    Date of Patent: April 8, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Duane A. Burnett, Zhiqiang Zhao, David Cole, Hubert Josien, Dmitri A. Pissarnitski, Thavalakulamgar Sasikumar, Wen-Lian Wu, Martin Domalski